Selenium, glutathione peroxidase (GSH-Px) and lipid peroxidation products before and after selenium supplementation.
Treated phenylketonuric (PKU) children are at risk of selenium deficiency. We have studied 15 treated PKU children and 30 control children. We observed significantly lower (P less than 0.0005) plasma and erythrocyte selenium, as well as significantly lower (P less than 0.0005) plasma and erythrocyte glutathione peroxidase activities (GSH-Px) in PKU children than in controls. The lipid peroxidation products, evaluated as plasma malondialdehyde (MDA), was higher (P less than 0.0005) in PKU children than in controls. Specific oral sodium selenite supplementation (Selenium: 0.13 mumol/kg/day) resulted in a rapid increase of plasma selenium and GSH-Px activity, and after 10 days and 1 month respectively significant difference is no longer observed between PKU children and controls values. Statistically significant differences in erythrocyte selenium, erythrocyte GSH-Px activity and plasma MDA between PKU and control children disappear after respectively 2 months, 4 months and 6 months of selenium supplementation.
Wilke
B C
BC
Faculté de Medecine, Hôpital Albert Michallon, Grenoble, France.
Vidailhet
M
M
Favier
A
A
Guillemin
C
C
Ducros
V
V
Arnaud
J
J
Richard
M J
MJ
D002648:Child; D002675:Child, Preschool; D005260:Female; D005979:Glutathione Peroxidase / Q000097:blood*; D006801:Humans; D007223:Infant; D008297:Male; D008315:Malondialdehyde / Q000097:blood*; D010661:Phenylketonurias / Q000097:blood* / Q000628:therapy; D012643:Selenium / Q000008:administration & dosage / Q000097:blood* / Q000172:deficiency
D008315:Malondialdehyde; D005979:Glutathione Peroxidase; D012643:Selenium